Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program
AGD members are using the population-level insights to uncover novel drug targets
SAN DIEGO, March 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. Insights from the AGD database are being leveraged to accelerate drug target discovery, therapeutic research and clinical development.
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.